1,4-雙(4-氨苯氧基)苯(>98.0%(GC)(T))是實(shí)驗(yàn)*,價(jià)格合理,全國(guó)包郵,我們公司提供的產(chǎn)品通過(guò)全面檢測(cè),嚴(yán)格質(zhì)量控制,質(zhì)量有保障,可滿足不同層次的科研需要。
產(chǎn)品名稱(chēng) | | 發(fā)貨地 | 包裝 |
1,4-雙(4-氨苯氧基)苯(>98.0%(GC)(T)) | 3491-12-1 | 上海 | 按客戶要求包裝 |
產(chǎn)品名稱(chēng):1,4-雙(4-氨苯氧基)苯(>98.0%(GC)(T))
英文名稱(chēng):1,4-Bis(4-aminophenoxy)benzene
:3491-12-1
質(zhì)量規(guī)格:>98.0%(GC)(T)
保存條件:陰涼干燥,避光環(huán)境保存
包裝說(shuō)明:毫克級(jí)、克級(jí)等多種級(jí)別。
發(fā)貨方式:快遞(現(xiàn)貨供應(yīng),特殊產(chǎn)品接受定制)
運(yùn)輸方面:現(xiàn)貨供應(yīng),一般為快遞運(yùn)輸,江浙滬隔天到,外地及偏遠(yuǎn)地方三至五天時(shí)間到貨。
儲(chǔ)存條件:避光、干燥陰涼處封閉貯存,嚴(yán)禁與有毒、有害物品混放、混運(yùn)。本品為非危險(xiǎn)品,可按一般化學(xué)品運(yùn)輸,輕搬動(dòng)輕放,防止日曬、雨淋。
產(chǎn)品來(lái)源:國(guó)內(nèi)外*試劑供應(yīng)商,產(chǎn)品100%有保障
備注:以上描述,僅作參考,并不表示您收到的產(chǎn)品,與此項(xiàng)描述*相符,產(chǎn)品的出廠標(biāo)準(zhǔn),請(qǐng)參見(jiàn)質(zhì)量標(biāo)準(zhǔn)。
1,4-雙(4-氨苯氧基)苯(>98.0%(GC)(T))可滿足您實(shí)驗(yàn)所需,量大更優(yōu)惠,*,公司同類(lèi)相關(guān)產(chǎn)品:
Ephrin A5 蛋白激酶A5受體抗體
epithelial Sodium Channel gamma 上皮鈉離子通道蛋白γ/γENaC抗體
ETS2 癌基因ETS2抗體
Endothelin 3 內(nèi)皮素3抗體
phospho-ERK5 磷酸化細(xì)胞外信號(hào)調(diào)節(jié)激酶5抗體
phospho-ERK5 磷酸化細(xì)胞外信號(hào)調(diào)節(jié)激酶5抗體
ERK4 細(xì)胞外信號(hào)調(diào)節(jié)激酶4抗體
E.coli O157:H7 腸出血性大腸桿菌埃希氏菌O157:H7抗體
phospho-ERK1 + ERK2 磷酸化絲裂原活化蛋白激酶ERK抗體
EMR2 CD312抗體
eIF4EBP1 eIF4E結(jié)合蛋白抗體
Phospho-EGFR 磷酸化表皮生長(zhǎng)因子受體抗體
Phospho-EGFR 磷酸化表皮生長(zhǎng)因子受體抗體
Ephrin A1 Receptor 肝配蛋白A1受體抗體
eIF2C2 真核翻譯起始因子2C2抗體
EYA2 眼睛發(fā)育缺失蛋白EYA2抗體
EYA4 EYA4蛋白抗體
ELK4 血清反應(yīng)因子輔助蛋白1抗體
ELMO2 吞噬細(xì)胞運(yùn)動(dòng)蛋白2抗體
EPB41 紅細(xì)胞膜條帶4.1蛋白抗體
phospho-EPO Receptor 磷酸化紅細(xì)胞生成素受體抗體
E2F7 轉(zhuǎn)錄調(diào)節(jié)因子E2F7抗體
EAAT4 膠質(zhì)細(xì)胞運(yùn)載蛋白4抗體
EBP1 erbB3結(jié)合蛋白1抗體
ECH1 烯酰水合酶1抗體
ECHDC2 烯酰水合酶含結(jié)構(gòu)域蛋白2抗體
EDAR 腫瘤壞死因子受體超家族成員EDAR抗體
EDC4 自身抗原抗體EDC4抗體
UBR5 E3泛素蛋白連接酶EDD抗體
EED 胚胎外胚層發(fā)育蛋白EED抗體
KAT3B/Ep300 轉(zhuǎn)錄接頭蛋白EP300抗體
Endothelial lipase 內(nèi)皮脂肪酶抗體
ENO1 MYC啟動(dòng)子結(jié)合蛋白1抗體
ERp29 內(nèi)質(zhì)網(wǎng)蛋白29抗體
ECHS1 烯脂酰水解酶抗體CAY10614 (25 mg) N-cyclopentyl-N,N-dimethyl-3,4-bis(tetradecyloxy)-benzenemethanaminium, iodide; CAY10614
CAY10614 (5 mg) N-cyclopentyl-N,N-dimethyl-3,4-bis(tetradecyloxy)-benzenemethanaminium, iodide; CAY10614
(R)-Lisofylline (1 mg) 3,7-dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; (-)-Lisofylline|(R)-LSF; (R)-Lisofylline
(R)-Lisofylline (10 mg) 3,7-dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; (-)-Lisofylline|(R)-LSF; (R)-Lisofylline
(R)-Lisofylline (25 mg) 3,7-dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; (-)-Lisofylline|(R)-LSF; (R)-Lisofylline
(R)-Lisofylline (5 mg) 3,7-dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; (-)-Lisofylline|(R)-LSF; (R)-Lisofylline
(S)-Lisofylline (1 mg) 3,7-dihydro-1-[5S-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; (+)-Lisofylline|(S)-LSF; (S)-Lisofylline
(S)-Lisofylline (10 mg) 3,7-dihydro-1-[5S-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; (+)-Lisofylline|(S)-LSF; (S)-Lisofylline
(S)-Lisofylline (25 mg) 3,7-dihydro-1-[5S-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; (+)-Lisofylline|(S)-LSF; (S)-Lisofylline
(S)-Lisofylline (5 mg) 3,7-dihydro-1-[5S-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; (+)-Lisofylline|(S)-LSF; (S)-Lisofylline
1,4-雙(4-氨苯氧基)苯(>98.0%(GC)(T))ACS 67 (1 mg) 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl ester, 5Z-heptenoic acid; ACS 67
ACS 67 (10 mg) 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl ester, 5Z-heptenoic acid; ACS 67